SUVRETTA CAPITAL MANAGEMENT, LLC 13D and 13G filings for EyePoint Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 12:00 pm Purchase | 2023-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | SUVRETTA CAPITAL MANAGEMENT, LLC | 4,774,389 9.990% | 1,363,179 (+39.96%) | Filing |
| 2023-02-13 10:23 am Sale | 2022-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | SUVRETTA CAPITAL MANAGEMENT, LLC | 3,411,210 9.990% | -70,899 (-2.04%) | Filing |
| 2022-02-11 4:24 pm Purchase | 2021-12-31 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | SUVRETTA CAPITAL MANAGEMENT, LLC | 3,482,109 9.990% | 1,886,945 (+118.29%) | Filing |
| 2021-07-26 5:21 pm Purchase | 2021-07-14 | 13G | EyePoint Pharmaceuticals, Inc. EYPT | SUVRETTA CAPITAL MANAGEMENT, LLC | 1,595,164 5.600% | 1,595,164 (New Position) | Filing |